Trends in central nervous system-active polypharmacy among people with multiple sclerosis.

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY

Multiple Sclerosis Journal Pub Date : 2024-08-01 Epub Date: 2024-05-15 DOI:10.1177/13524585241251986

Hayden Naizer, Joseph Wozny, Trudy Millard Krause, Ethan Huson, Leorah Freeman

{"title":"Trends in central nervous system-active polypharmacy among people with multiple sclerosis.","authors":"Hayden Naizer, Joseph Wozny, Trudy Millard Krause, Ethan Huson, Leorah Freeman","doi":"10.1177/13524585241251986","DOIUrl":null,"url":null,"abstract":"Background: People with multiple sclerosis (pwMS) are at risk of concurrently using multiple central nervous system (CNS)-active drugs, yet the prevalence of CNS-active polypharmacy remains unmeasured in pwMS.Objective: The objective is to measure the prevalence of CNS-active polypharmacy in pwMS.Methods: This serial, cross-sectional study measured CNS-active polypharmacy in people with MS in the United States from 2008 to 2021 using insurance claims data. CNS-active polypharmacy was defined as the concurrent prescription of ⩾3 CNS-active drugs for >30 continuous days. CNS-active drugs included antidepressants, antiepileptics, antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants.Results: The number of subjects included at each time point ranged from 23,917 subjects in 2008 to 55,797 subjects in 2021. In 2021, subjects with CNS-active polypharmacy were more likely to be 46-65 years of age and have CNS-related comorbidities compared to those without CNS-active polypharmacy. From 2008 to 2021, the age-adjusted prevalence of CNS-active polypharmacy among female subjects increased from 19.8% (95% confidence interval (CI) = 19.1-20.4) to 26.4% (95% CI = 25.9-26.8) versus 15.9% (95% CI = 14.8-17.0) to 18.6% (95% CI = 17.9-19.2) in male subjects.Conclusion: The prevalence of CNS-active polypharmacy has increased among people with MS with a growing disparity by sex.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"1139-1150"},"PeriodicalIF":4.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363472/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241251986","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: People with multiple sclerosis (pwMS) are at risk of concurrently using multiple central nervous system (CNS)-active drugs, yet the prevalence of CNS-active polypharmacy remains unmeasured in pwMS.

Objective: The objective is to measure the prevalence of CNS-active polypharmacy in pwMS.

Methods: This serial, cross-sectional study measured CNS-active polypharmacy in people with MS in the United States from 2008 to 2021 using insurance claims data. CNS-active polypharmacy was defined as the concurrent prescription of ⩾3 CNS-active drugs for >30 continuous days. CNS-active drugs included antidepressants, antiepileptics, antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants.

Results: The number of subjects included at each time point ranged from 23,917 subjects in 2008 to 55,797 subjects in 2021. In 2021, subjects with CNS-active polypharmacy were more likely to be 46-65 years of age and have CNS-related comorbidities compared to those without CNS-active polypharmacy. From 2008 to 2021, the age-adjusted prevalence of CNS-active polypharmacy among female subjects increased from 19.8% (95% confidence interval (CI) = 19.1-20.4) to 26.4% (95% CI = 25.9-26.8) versus 15.9% (95% CI = 14.8-17.0) to 18.6% (95% CI = 17.9-19.2) in male subjects.

Conclusion: The prevalence of CNS-active polypharmacy has increased among people with MS with a growing disparity by sex.

查看原文本刊更多论文

多发性硬化症患者服用中枢神经系统活性药物的趋势。

背景：多发性硬化症患者（pwMS）有同时使用多种中枢神经系统（CNS）活性药物的风险，但中枢神经系统活性多种药物在多发性硬化症患者中的使用率仍未得到测量：目的：测量中枢神经系统活性药物的使用率：这项连续性横断面研究使用保险理赔数据测量了 2008 年至 2021 年美国多发性硬化症患者的中枢神经系统活性多重药物治疗情况。中枢神经系统活性药物的定义是同时处方 ⩾3 种中枢神经系统活性药物，且连续处方时间超过 30 天。中枢神经系统活性药物包括抗抑郁药、抗癫痫药、抗精神病药、苯二氮卓类药物、非苯二氮卓类苯二氮卓受体激动剂催眠药、阿片类药物和骨骼肌松弛剂：每个时间点纳入的受试者人数从 2008 年的 23,917 人到 2021 年的 55,797 人不等。与未使用中枢神经系统活性多种药物的受试者相比，2021 年使用中枢神经系统活性多种药物的受试者更有可能年龄在 46-65 岁之间，并患有中枢神经系统相关的合并症。从2008年到2021年，经年龄调整后，女性受试者中中枢神经系统活性多种药物的流行率从19.8%（95%置信区间（CI）=19.1-20.4）增加到26.4%（95% CI = 25.9-26.8），而男性受试者中中枢神经系统活性多种药物的流行率从15.9%（95% CI = 14.8-17.0）增加到18.6%（95% CI = 17.9-19.2）：结论：中枢神经系统活性药物的使用率在多发性硬化症患者中有所上升，且性别差异越来越大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585